Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Health Ministers Back Stronger Pandemic Role For EMA

Plans Include Emergency Task Force To Advise Drug And Vaccine Developers

Executive Summary

Proposals for establishing a ‘European Health Union’ include measures to give the EU regulator more say in monitoring and mitigating potential and actual shortages of drugs and devices in the event of serious public health crises.

You may also be interested in...



Coronavirus Notebook: EU Industry Claims ‘Undeniable’ Role Of IP, UK Targets Younger At-Risk Groups For Vaccination

Draft EU legislation on tackling cross-border health threats has taken another step forward, as health authorities say the Delta variant of the SARS-CoV-2 virus will be the “globally dominant strain” over the coming months.

EU Politicians Want Stronger Role For European Medicines Agency In Health Risk Assessment

Legislation that will help to build a future “European Health Union” is making its way through the EU legislative process. It includes a greater role for EU health agencies in making preparations for future health emergencies.

Coronavirus Notebook: EMA Explains How To Get A Modified Vaccine Approved, UK Starts Oxford/AZ Variant Vaccine Trial

Draft legislation on strengthening the European Medicines Agency’s role in health crises has cleared another hurdle, and the European Commission is inviting companies to a matchmaking event aimed at scaling up the development and production of COVID-19 therapeutics.

Related Content

Topics

UsernamePublicRestriction

Register

PS144484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel